^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MSK-IMPACT

    Company:
    Memorial Sloan-Kettering Cancer Center
    Type:
    FDA Approved
    Related tests:
    11ms
    Michael Walsh presented MSK-IMPACT data on POT1 showing a possible association with lung cancer & @KMaxwellLab discussing what we should do about POT1 testing clinically at #ASCO23 (@HHampel1)
    Clinical
    |
    POT1 (Protection of telomeres 1)
    |
    MSK-IMPACT
    1year
    @DSolit our Keynote speaker highlights @MSKCancerCenter MSKimpact sequencing program and defining actionable genomic alterations in #BladderCancer and other tumors @AmerUrological JHU/AUA @HopkinsMedicine @hopkinskimmel @djmcconkey ()
    MSK-IMPACT
    1year
    "At 7% of cholangiocarcinomas/gall bladder cancers, a HER2 mutant-only trial would have been difficult if not impossible with older clinical trial designs. Below is our cholangio/GB MSK-IMPACT as of today (>1350 pts profiled as part of the MSK-IMPACT initiative over 9 years)." (@DSolit)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    MSK-IMPACT
    over1year
    🔥Molecular classification of appendiceal adenocarcinoma @JCO_ASCO https://t.co/fitcM2MZqf ✅164 pts MSK-IMPACT 👉25% druggable🎯GA ✅3 subtypes: 👉mRAS,GNAS WT, TP53 WT: clinically indolent 👉mGNAS: CTx resistant 👉mTP53: aggressive, highly aneuploid @myESMO @OncoAlert ()
    Clinical
    |
    TP53 (Tumor protein P53) • GNAS (GNAS Complex Locus)
    |
    TP53 wild-type
    |
    MSK-IMPACT
    over1year
    Happening now: dr @antoniomarraMD @MSKCancerCenter reporting on implications of #APOBEC & other mutational signatures on sensitivity to #ET (with/out #CDK 4/6) in HR+ #MBC #bcsm #MSKimpact #ESMO22 @myESMO @curijoey ()
    CDK4 (Cyclin-dependent kinase 4)
    |
    MSK-IMPACT
    over2years
    #SABCS2021 MSK-IMPACT host-somatice interactions, cont. BRCA2 and RB1 LOH loss are highly correlated. BRCA2 patients have worse outcomes with CDK 4/6 therapy, c/w what you would expect. Cool biology. (@GeorgeSledge51)
    Clinical
    |
    BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    MSK-IMPACT
    over2years
    #SABCS2021 Germline-somatic interactions and clinical outcomes from MSK-IMPACT database. Focus on BRCA1/2, Chek2, PALB2, ATM. BRCA1/2 for this presentation, with 122 and 101, respectively. TP53 excluded by ATM. BRCA and TP53 enriched. BRCA2 excludes PIK3CA but enriched RB1. (@GeorgeSledge51)
    Clinical data • Clinical
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    MSK-IMPACT
    over2years
    💡To find #metastatic recurrence biomarkers of TNBC treated by neoadjuvant chemotherapy and anti-EGFR #antibodies, the #authors evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, #gene arrays, Nanostring technology, and TIL assessment on H&E🤔👏 (@Dr_Ivanoncologo)
    Clinical
    |
    MSK-IMPACT
    almost3years
    Can MSK-IMPACT Test be done from India for TNBC patients ?? (@drmcshekhar)
    Clinical
    |
    MSK-IMPACT
    3years
    🌟NEW in @NatureCancer: Prospective pan-cancer germline testing using #MSKIMPACT informs clinical translation in 751 patients with pediatric solid tumors by @MichaelWalshMSK @ahmetz & co. #PediatricCancer #CancerGenetics Read it👇🏻 https://t.co/c8tFvldE5Z https://t.co/XxyVh7lMog (@alexia_zz)
    Clinical • Pan tumor
    |
    MSK-IMPACT
    over3years
    #TumorMutationalBurden a #Predictive #Biomarker in #SolidTumors https://t.co/a4YBRrJgwm #Oncology #MolecularOncology #PrecisionOncology #Immunotherapy #PDL1 #NGS #WholeExomeSequencing #MSKImpact #FoundationOneCDx #Mutation #Somatic #Melanoma #LungCancer @FASinicropeMD @AACR (@MDJDPathology)
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    FoundationOne® CDx • MSK-IMPACT
    over3years
    Worth mentioning that appreciation for this testing movement has been inspired by the work of @MPishvaian (#KYT) and @EileenMOReilly (#mskimpact); and with @pashtoonkasi leading the way on #ctDNA, and @DocCatenacci for ICI/CPI in #gastric and #esophageal #cancer #oncology 🙏🏽 (@VelocirapmTOR)
    MSK-IMPACT
    over3years
    A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Cancer @HelenaYu923 @alexdrilon #MSKimpact https://t.co/gAInmHIzdt (@MLadanyi)
    MSK-IMPACT
    over3years
    We are happy to share Dr. Evan Rosenbaum & @sandrapdangelo et al’s paper on synovial #sarcoma, recently published in @CCR_AACR. The authors conclude that targeted gene panels like MSK-IMPACT can accurately report HLA type. Read it here: https://t.co/3g2rEtK2gR (@MSKSarcoma)
    EPHB3 (EPH Receptor B3)
    |
    MSK-IMPACT
    4years
    "Yes! We need to push to do thorough molecular testing in people with NSCLC. First step, a high sensitivity DNA-approach (like MSK-IMPACT). If doesn’t reveal driver, then RNA. My colleagues reported a US series here https://t.co/sIqEF292P9 @MLadanyi @alexdrilon" (@RielyMD)
    MSK-IMPACT